ATE522515T1 - Modulatoren der dopamin-neurotransmission - Google Patents

Modulatoren der dopamin-neurotransmission

Info

Publication number: ATE522515T1
Authority: AT; Austria
Prior art keywords: modulators; dopamine neurotransmission; compounds; relates; neurotransmission
Prior art date: 2008-04-29

Application number

AT09738154T

Other languages

English (en)

Inventor

Clas Sonesson

Peder Svensson

Mikael Andersson

Original Assignee

Nsab Af Neurosearch Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-29

Filing date

2009-04-28

Publication date

2011-09-15

2009-04-28 Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab

2011-09-15 Application granted granted Critical

2011-09-15 Publication of ATE522515T1 publication Critical patent/ATE522515T1/de

Links

VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 4
229960003638 dopamine Drugs 0.000 title abstract 2
230000005062 synaptic transmission Effects 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
RKMLJTKQHHUYKR-UHFFFAOYSA-N 4h-1,3-benzodioxin-2-ylmethanamine Chemical class C1=CC=C2OC(CN)OCC2=C1 RKMLJTKQHHUYKR-UHFFFAOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Liquid Crystal Substances (AREA)
Steroid Compounds (AREA)

AT09738154T 2008-04-29 2009-04-28 Modulatoren der dopamin-neurotransmission ATE522515T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200800600		2008-04-29
US4905708P	2008-04-30	2008-04-30
PCT/EP2009/055140 WO2009133110A1 (en)	2008-04-29	2009-04-28	Modulators of dopamine neurotransmission

Publications (1)

Publication Number	Publication Date
ATE522515T1 true ATE522515T1 (de)	2011-09-15

Family

ID=40937591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09738154T ATE522515T1 (de)	2008-04-29	2009-04-28	Modulatoren der dopamin-neurotransmission

Country Status (10)

Country	Link
US (1)	US8492372B2 (de)
EP (1)	EP2271638B1 (de)
JP (1)	JP5548853B2 (de)
CN (1)	CN102015674B (de)
AT (1)	ATE522515T1 (de)
AU (1)	AU2009242095A1 (de)
CA (1)	CA2722986A1 (de)
DK (1)	DK2271638T3 (de)
MX (1)	MX2010011498A (de)
WO (1)	WO2009133110A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009133107A1 (en)	2008-04-29	2009-11-05	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Modulators of dopamine neurotransmission
JP2011519839A (ja) *	2008-04-29	2011-07-14	エヌエスエイビー、フィリアルアヴノイロサーチスウェーデンエービー、スヴェーリエ	ドーパミン神経伝達のモジュレーター
CA2832874C (en)	2011-04-19	2019-06-11	Integrative Research Laboratories Sweden Ab	Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
KR101758583B1 (ko) *	2013-12-12	2017-07-14	(주)바이오팜솔루션즈	통증을 치료 또는 완화하기 위한 설파메이트 유도체 화합물
CN106928147A (zh) *	2017-03-14	2017-07-07	华东师范大学	三环二萜类似物及其制备方法、及其在制备抗前列腺癌药物中的应用
DK3976581T3 (da)	2019-05-24	2024-01-22	Irl 790 Ab	Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3058980A (en) *		1962-10-16		Substitution products of benzo-
US2906757A (en) *		1959-09-29		Their preparation
DE1110175B (de) *	1957-01-08	1961-07-06	Rhone Poulenc Sa	Verfahren zur Herstellung von Benzodioxanderivaten
US3851062A (en) *	1973-08-01	1974-11-26	Minnesota Mining & Mfg	Method of suppressing weight gain
US4056540A (en) *	1974-01-01	1977-11-01	Bristol-Myers Company	4-Phenyl-1,3-benzodioxans
US5189171A (en) *	1991-06-21	1993-02-23	American Home Products Corporation	Antipsychotic benzodioxan derivatives
US5166367A (en) *	1991-06-21	1992-11-24	American Home Products Corporation	Antipsychotic benzodioxan derivatives
US5126366A (en) *	1991-06-21	1992-06-30	American Home Products Corporation	Aminophenoxyalkyl derivatives of benzodioxan
DE4135474A1 (de) *	1991-10-28	1993-04-29	Bayer Ag	2-aminomethyl-chromane
US5235055A (en) *	1992-09-02	1993-08-10	American Home Products Corporation	Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) *	1992-09-03	1993-09-14	American Home Products Corporation	Antipsychotic chroman derivatives of benzodioxanmethylamine
WO1996038435A1 (en) *	1995-05-30	1996-12-05	Abbott Laboratories	Dopamine agonists
US5663194A (en) *	1995-07-25	1997-09-02	Mewshaw; Richard E.	Chroman-2-ylmethylamino derivatives
AR004229A1 (es) *	1995-11-06	1998-11-04	Wyeth Corp	Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
FR2791675B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
SE9904724D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
SE9904723D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
GB0007376D0 (en)	2000-03-28	2000-05-17	Knoll Ag	Therapeutic agents
CA2461381A1 (en)	2001-10-04	2003-04-10	Wyeth	Chroman derivatives as 5-hydroxytryptamine-6 ligands
JP2007527412A (ja) *	2003-10-24	2007-09-27	エグゼリクシス，インコーポレイテッド	Ｔａｏキナーゼモジュレーターおよび使用方法
MXPA06012621A (es)	2004-05-05	2006-12-15	Hoffmann La Roche	Arilsulfonil benzodioxanos utiles para la modulacion del receptor 5-ht6, el receptor 5-ht2a o ambos.
MXPA06013941A (es) *	2004-06-08	2007-12-10	Neurosearch Sweden Ab	Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
TW200612905A (en) *	2004-06-16	2006-05-01	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en)	2004-06-16	2013-01-31	Janssen Pharmaceutica Nv	Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US7713954B2 (en) *	2004-09-30	2010-05-11	Roche Palo Alto Llc	Compositions and methods for treating cognitive disorders
RU2007139543A (ru) *	2005-04-22	2009-05-27	Вайет (Us)	Производные бензодиоксана и бензодиоксолана и их применение
SE529246C2 (sv) *	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US8937096B2 (en) *	2005-12-19	2015-01-20	Janssen Pharmaceutica Nv	Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
AR058389A1 (es) *	2005-12-19	2008-01-30	Janssen Pharmaceutica Nv	Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) *	2005-12-19	2014-04-08	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) *	2005-12-19	2014-05-06	Janssen Pharmaceutica Nv	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155824A1 (en) *	2005-12-19	2007-07-05	Smith-Swintosky Virginia L	Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
WO2007120596A1 (en) *	2006-04-12	2007-10-25	Wyeth	DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AR060493A1 (es) *	2006-04-18	2008-06-18	Wyeth Corp	Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
JP2009537635A (ja) *	2006-05-19	2009-10-29	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	癲癇の処置のための共同−療法
TWI457122B (zh)	2007-07-20	2014-10-21	Orion Corp	作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP2011519839A (ja) *	2008-04-29	2011-07-14	エヌエスエイビー、フィリアルアヴノイロサーチスウェーデンエービー、スヴェーリエ	ドーパミン神経伝達のモジュレーター
WO2009133107A1 (en) *	2008-04-29	2009-11-05	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Modulators of dopamine neurotransmission

2009
- 2009-04-28 DK DK09738154.5T patent/DK2271638T3/da active
- 2009-04-28 JP JP2011506691A patent/JP5548853B2/ja not_active Expired - Fee Related
- 2009-04-28 CA CA2722986A patent/CA2722986A1/en not_active Abandoned
- 2009-04-28 AT AT09738154T patent/ATE522515T1/de active
- 2009-04-28 AU AU2009242095A patent/AU2009242095A1/en not_active Abandoned
- 2009-04-28 WO PCT/EP2009/055140 patent/WO2009133110A1/en not_active Ceased
- 2009-04-28 CN CN200980115129.4A patent/CN102015674B/zh not_active Expired - Fee Related
- 2009-04-28 US US12/990,043 patent/US8492372B2/en not_active Expired - Fee Related
- 2009-04-28 EP EP09738154A patent/EP2271638B1/de not_active Not-in-force
- 2009-04-28 MX MX2010011498A patent/MX2010011498A/es active IP Right Grant

Also Published As

Publication number	Publication date
JP5548853B2 (ja)	2014-07-16
JP2011518859A (ja)	2011-06-30
AU2009242095A1 (en)	2009-11-05
WO2009133110A1 (en)	2009-11-05
US8492372B2 (en)	2013-07-23
US20110112065A1 (en)	2011-05-12
CA2722986A1 (en)	2009-11-05
MX2010011498A (es)	2010-11-12
EP2271638B1 (de)	2011-08-31
DK2271638T3 (da)	2011-11-28
CN102015674A (zh)	2011-04-13
EP2271638A1 (de)	2011-01-12
CN102015674B (zh)	2014-10-29

Legal Events

Date

Code

Title

Description

2012-03-15

UEP

Publication of translation of european patent specification

Ref document number: 2271638

Country of ref document: EP

Publication	Publication Date	Title
CY1117143T1 (el)	2017-04-05	Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
MA32383B1 (fr)	2011-06-01	DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MA32508B1 (fr)	2011-07-03	Composes organiques
MX2010008714A (es)	2010-09-24	Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
JOP20180103A1 (ar)	2019-01-30	مركب صيدلاني
CO6321282A2 (es)	2011-09-20	Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MX2010001754A (es)	2010-05-14	Derivados de azepina como inhibidores de gamma secretasa.
EA201170198A1 (ru)	2011-08-30	Фармацевтические композиции, содержащие лиганды рецептора дофамина
ECSP11011411A (es)	2011-11-30	Derivados de prolina como inhibidores de catepsina
CL2011002857A1 (es)	2012-06-08	Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
JO3425B1 (ar)	2019-10-20	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
UA116467C2 (uk)	2018-03-26	Модулятори p2x7
UA110600C2 (uk)	2016-01-25	Спосіб отримання захищених похідних l-аланіну
DK2078010T3 (da)	2014-04-28	Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
EA201001205A1 (ru)	2011-04-29	Соединения, содержащие циклобутоксигруппу
EA201101116A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112012011328A2 (pt)	2016-11-22	inibidores de akt
EA201101118A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA107671C2 (en)	2015-02-10	N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
ATE499367T1 (de)	2011-03-15	1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
GT200900309A (es)	2012-01-26	Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
IN2012DN05125A (de)	2015-10-23
UA106889C2 (uk)	2014-10-27	Похідні n1-ацил-5-фторпіримідинону
MX2010009147A (es)	2010-09-07	Derivados de pirrolidinilo y usos de los mismos.
DK2271638T3 (da)	2011-11-28	Modulatorer af dopaminneurotransmission